Construction, characterization, and immunization of nanoparticles that display a diverse array of influenza HA trimers

Abstract

Current influenza vaccines do not elicit broadly protective immune responses against multiple strains. New strategies to focus the humoral immune response to conserved regions on influenza antigens are therefore required for recognition by broadly neutralizing antibodies. It has been suggested that B-cells with receptors that recognize conserved epitopes would be preferentially stimulated through avidity effects by mosaic particles presenting multiple forms of a variable antigen. We adapted SpyCatcher-based platforms, AP205 virus-like particles (VLPs) and mi3 nanoparticles (NPs), to covalently co-display SpyTagged hemagglutinin (HA) trimers from group 1 and group 2 influenza A strains. Here we show successful homotypic and heterotypic conjugation of up to 8 different HA trimers to both VLPs and NPs. We characterized the HA-VLPs and HA-NPs by cryo-electron tomography to derive the average number of conjugated HAs and their separation distances on particles, and compared immunizations of mosaic and homotypic particles in wild-type mice. Both types of HA particles elicited strong antibody responses, but the mosaic particles did not consistently elicit broader immune responses than mixtures of homotypic particles. We conclude that covalent attachment of HAs from currently-circulating influenza strains represents a viable alternative to current annual influenza vaccine strategies, but in the absence of further modifications, is unlikely to represent a method for making a universal influenza vaccine.

Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models

“…SpyCatcher003-mi3 nanoparticles ( 80 ) were expressed in BL21 (DE3)-RIPL Escherichia coli (Agilent) transformed with the pET28a His6-SpyCatcher003-mi3 gene (Addgene) as described ( 34 , 82 ). Briefly, transformed bacterial cell pellets were lysed in the presence of 2.0 mM PMSF (Sigma).…”

Induction of Broadly Cross-Reactive Antibody Responses to SARS-CoV-2 Variants by S1 Nanoparticle Vaccines

“…Finally, the I53-50 NP was coassembled from 20 trimeric I53-50A and 12 pentameric I53-50B subunits to form an icosahedral nanoparticle ( 48 , 49 ). These three nanoparticles were found to be safe, stable, and easy to produce in previous studies ( 32 , 50 – 52 ).…”

RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge

“…1A ). This technology has been used to improve the immunogenicity of viral vaccines against human cytomegalovirus, influenza, and HIV ( 28 – 31 ). Here, our studies were comprised of two main goals.…”